Cigna raises long-term adjusted EPS growth target to 10%-14%; reaffirms FY2024 guidance of at least $28.25

Cigna Group

Long-term average annual adjusted EPS growth target raised to 10%-14% from prior target.
2024 adjusted EPS guidance reaffirmed at least $28.25 per share.
Launches EncircleRx: industry-first financial guarantee for GLP-1s to help cap employer costs.
Evernorth Behavioral Care Group launched; guarantees appointment within 72 hours, scales by 2025.
Evernorth plans Humira biosimilar at $0 out-of-pocket for eligible Accredo patients by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.